



17TH MARCH - 21ST MARCH 2025



the www.progressiveshares.com

Equities | Derivatives | Commodities | Currency | PMS | Depository | Mutual Funds | NBFC | e-Broking

DOMESTIC:

- IndusInd Bank stable, be wary of speculative reports: RBI
- Blackstone to acquire 40% stake in KoltePatil Developers
- KEC International secures new orders worth Rs12.67bn
- G R Infraprojects selected for Agra-Gwalior road project
- Welspun Corp bags new order worth Rs24bn in US
- Tata Motors to hike CV prices upto 2% starting 1st April, 2025
- SBI shelves USD1.7bn fund raising as yields elevated: Sources
- Gene therapy for blood cancer shows 73% response rate in clinical trials
- IRCON-BRC JV wins Rs10.96bn EPC contract for new Shillong secretariat
- Morepen Labs launches new cost-effective drug for diabetes, heart failure and kidney disease

Equities | Derivatives | Commodities | Currency | PMS | Dep

- Bajaj Finserv to buy Allianz's 26% stake in insurance JVs for Rs241.8bn
- BPCL launches world's first hydrogen-powered VTOL aviation ecosystem
- Transrail Lighting bags new Rs1,647cr orders in global markets
- Aurobindo Pharma arm gets USFDA EIR for Telangana unit
- Ajanta Pharma expands the formulation facility at Pithampur
- UltraTech Cement commissions additional 1.2mtpa production capacity
- Wipro, Tech Mahindra, L&T Tech Services announce partnership with Nvidia
- NHPC Board approves Rs63bn borrowing plan for FY26
- Texmaco Rail Engineering sold 22,000 equity shares in Texmaco Defence
- Hero MotoCorp enters electric three-wheeler biz with investment worth Rs525cr in Euler Motors
- Sun Pharmaceuticals completes 100% acquisition in Antibe Therapeutics Inc., Canada
- Torrent Power, Gama Infraprop win tender to supply gas-based power
- Alembic Global Holding SA, (WoS of Alembic) incorporates a WoS in USA named Alembic Lifesciences Inc.
- Hindustan Unilever Board okays acquiring 14.3% stake in Lucro Plastecycle
- JSW Energy Board approves allotment of 80,000 NCDs worth Rs800cr
- Piramal Pharma arm, Irish firm get UKMHRA approval for Neoatricon in UK
- JK Lakshmi Cement gets Rs45.6cr demand from income tax authority
- PayU buys 43.5% stake in payment technology firm Mindgate Solutions for undisclosed sum

ECONOMY:

- India and US move forward with bilateral trade agreement, but no talks on reciprocal tariffs
- Trump tariff impact: India's Feb trade deficit narrows to lowest in over 3 years
- UK-India free trade pact inches closer after years of delays: Report

INDUSTRY:

- Crude import price falls to 42 month low
- India cuts China bulk-drug reliance
- Services exports may surpass merchandise shipments in FY26: Piyush Goyal



COVERAGE NEWS:

Alkem Laboratories Ltd: As per the earlier intimation of 7th Feb, 2025, Alkem Medtech Private Ltd, a wholly owned subsidiary of the company in India intends to acquire 100% stake of M/s. Bombay Ortho Industries Private Ltd. The share purchase agreement for the same has been executed.

EMS Ltd: The credit ratings on the bank facilities of the company have been upgraded by Crisil Ratings for the total bank loan facilities amounting to Rs6,250mn.

Salzer Electronics Ltd: The company has secured second order worth Rs500mn for Smart Energy Meters from a leading Advanced Metering Infrastructure Service Provider (AMISP) in India.

Sandhar Technologies Ltd: As an outcome to the board meeting held today; the acquisition of high pressure & low pressure aluminium die casting businesses of Sundaram-Clayton Ltd at Hosur Plant, and the slump sale of unit IV and unit II, (zinc die casting) from Sandhar Technologies Ltd to Sandhar Ascast Private Ltd (WoS) has been approved. The board has also reviewed and approved the sale of its entire 50% stake in one of the JV namely, Jinyoung Sandhar Mechatronics Private Ltd.

Engineers India Ltd: Numaligarh Refinery Ltd (NRL) has awarded the job for EPCM services for 360KTPA polypropylene unit (PPU) project to EIL for a total estimated value of approx. Rs2,529.5mn plus GST.

Supreme Petrochem Ltd: The Board has approved a proposal to acquire 21,71,813 equity shares of Rs10 each (Rs397.6mn) of Xmold Polymers Pvt. Ltd (Xmold) from its existing shareholders, representing 100% of the equity share capital.

Indegene Ltd: (i) The company has announced the launch of a new center in London which aligns with the company's long-term growth strategy in Europe, reiterating its commitment to enable lifesciences clients in the region to be future-ready, (ii) The Board has approved investment in equity/preference shares of Indegene Ireland Ltd, a WoS of the company, upto an amount of EUR5.2mn, in one or more tranches.

Shilpa Medicare Ltd: (i) The USFDA conducted an inspection at Unit-2 of Shilpa Pharma Lifesciences Ltd, located at Raichur from 10th-14th March, 2025. The inspection was closed with Form 483 zero observations (second consecutive Form 483 zero inspection), (ii) Shilpa Biologicals Pvt. Ltd (SBPL, WoS of Shilpa Medicare) has entered into a binding term sheet with mAbTree Biologics AG, Switzerland for development, manufacture, marketing and sale of a New Biological Entity (NBE) for immuno-oncological applications.

J.B.Chemicals & Pharmaceuticals Ltd: The company's API manufacturing facility D9 located at Panoli, Gujarat was inspected by the USFDA from 10th-13th March, 2025. At the end of the inspection, the facility received no observations.

Royal Orchid Hotels Ltd: The company has launched two new properties viz; Regenta Baywatch Resort (133 keys) and Regenta Beach House (18 keys) in Goa.

Container Corporation of India Ltd: (i) The company has awarded a contract to Aanjaney Rail Pvt. Ltd. for the supply of 1350 Low Weight Low Height 25T axle load bogies and components, valued at Rs645.2mn (including GST), with completion expected by 5th August, 2026, (ii) The company has placed an order with M/s GATX India Pvt. Ltd., for the supply of 10 rakes of BLSS wagons on an operating lease for 10 years. The supplies are to be completed within 435 days, with the total order value amounting to Rs1920mn (excluding GST).

Timken India Ltd: The company has informed that the commercial production from the new manufacturing facility at Bharuch would commence in Q1FY26 as against the earlier timeline of Q4FY25 (indicated in Nov'24).

The Week That Went By:

The week was dominated by the bulls as throughout the week, the Index kept on compounding its gains to settle the week at the highest point of 23,350 with gains of 953.20 points. All the sectors ended the week in green with Realty and Media being the top performers. The Broader markets outshined the Frontline Index as Midcaps and Smallcaps advanced by 7.74% and 8.64% respectively.

Nifty50=23,350.40

BSE Sensex30=76,905.51

Nifty Midcap 100=51,850.75

Nifty Smallcap100=16,184.95






Nifty50 has ended its corrective phase with a strong bullish candle, breaking out of a **Falling Wedge Formation**, signaling a shift in trend towards a positive outlook. However, the hourly chart presents a different picture, showing extremely overbought conditions, and suggesting the need for a price revision. Immediate resistance is at 23,560, with support shifting higher to 23,200. Similarly, **BankNifty** has broken out from a **Double Bottom Formation**, with the upside capped at 51,600 and downside support at 50,000. The **Energy sector** has ended its secondary downtrend with a breakout from an **Inverted Head and Shoulder Formation**, indicating a potential trend reversal. Many components in this sector have already shown strong breakouts (already recommended the majority of them at lower levels), but entering at current levels is not advisable due to overbought conditions. The **IT sector** is also showing signs of a potential trend reversal from its long-term trendline support, warranting close monitoring. The **Pharma sector**, along with its constituents, has broken out from a **Falling Channel Formation**, making buying on dips a favorable strategy. Both the **PSU Banking and Realty sectors** have experienced pattern breakouts, signaling potential trend reversals. To summarise, almost all sectors have witnessed breakouts from different patterns, yet given the sharp rally throughout the week; many of these sectors and their components are in the overbought territory. Thereby, a short-term pullback or consolidation remains a possible scenario.



NIFTY 50 COMPONENTS (WEEKLY PERFORMANCE)

Adani Enterprises	6.41%	HDFC Bank	3.96%	ONGC	7.55%
Adani Ports	6.33%	HDFC Life	9.72%	PowerGrid	5.97%
Apollo Hospital	8.53%	Hero Motocorp	2.96%	Reliance	2.47%
Asian Paints	3.28%	Hindalco	2.79%	SBI Life	11.49%
Axis Bank	6.46%	HUL	3.24%	SBIN	3.64%
Bajaj Auto	7.73%			ShriRam Finance	9.05%
Bajaj Finance	5.90%	ICICI Bank	7.15%	Sun Pharma	6.56%
Bajaj Finserv	1.94%	IndusInd Bank	2.43%	Tata Consumer	2.01%
BEL	5.68%	INFY	1.04%		
Bharti Airtel	5.45%	ITC	(1.20%)	Tata Motors	7.30%
BPCL	5.80%	JSW Steel	6.05%	Tata Steel	4.23%
Britannia	1.86%	Kotak Bank	4.67%	TCS	1.96%
Cipla	3.81%	LT	7.09%	Tech Mahindra	(1.95%)
Coal India	7.16%			TITAN	5.38%
Dr. Reddy's Labs	8.67%	M&M	5.40%	Trent	2.33%
Eicher Motors	6.09%	Maruti	2.17%	Ultratech	5.04%
Grasim	4.67%	Nestle India	3.52%	Wipro	0.04%
HCL Tech	2.15%	NTPC	6.73%		


SECTORAL PERFORMANCE





Weekly Derivative:

Nifty50 has rebounded from the lower range of its long-term channel, driven by broad-based buying across sectors, gaining positive momentum, largely fueled by **the final phase of short covering**. Open Interest data indicates that the Index has the potential to advance toward the **23,600 strike**, where the **highest call writing** is observed, suggesting significant resistance at that level. At the same time, strong put open interest at the **23,200 strike provides support**, with **downside risk likely limited at the 23,000 strike**. In BankNifty, **fresh positions were built by put writers at the 50,500 strike** in the final hour of trading, a move that coincided with established call writing at this level. Given these last-minute additions, **short covering can be expected**, while the **51,000 strike**, with the highest call writing, is likely to serve as resistance on the upside.





SECTORAL GAINER



The **Realty segment** soared over 7.50% and outperformed the Frontline Index. All the constituents ended the week with gains where **Raymond (+20.92%) and Lodha (+12.82%)** were the top performers followed by **Mahindra Life (+9.75%) and Prestige (+9.45%).** As shown in the chart, the sector has given a breakout from a **Falling Wedge Formation** which indicates a trend reversal. Considering a strong rally during the week, buying on dips would be an ideal strategy.

With the Market sentiment being bullish, all the sectors have ended the week on a positive note.



DISCLAIMERS AND DISCLOSURES-

Progressive Share Brokers Pvt. Ltd. and its affiliates are a full-service, brokerage and financing group. Progressive Share Brokers Pvt. Ltd. (PSBPL) along with its affiliates are participants in virtually all securities trading markets in India. PSBPL started its operation on the National Stock Exchange (NSE) in 1996. PSBPL is a corporate trading member of Bombay Stock Exchange Limited (BSE), National Stock Exchange of India Limited (NSE) for its stock broking services and is Depository Participant with Central Depository Services Limited (CDSL) and is a member of Association of Mutual Funds of India (AMFI) for distribution of financial products.

PSBPL is SEBI registered Research Analyst under SEBI (Research Analysts) Regulations, 2014 with SEBI Registration No. INH000000859/Research Analyst BSE Enlistment No. 5049. PSBPL hereby declares that it has not defaulted with any stock exchange nor its activities were suspended by any stock exchange with whom it is registered in last five years. PSBPL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

PSBPL offers research services to clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

Other disclosures by Progressive Share Brokers Pvt. Ltd. (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company (s) covered in this report-:

· PSBPL or its associates financial interest in the subject company: NO

· Research Analyst (s) or his/her relative's financial interest in the subject company: NO

· PSBPL or its associates and Research Analyst or his/her relative's does not have any material conflict of interest in the subject company. The research Analyst or research entity (PSBPL) has not been engaged in market making activity for the subject company.

· PSBPL or its associates actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report: NO

· Research Analyst or his/her relatives have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report: NO

• PSBPL or its associates may have received any compensation including for brokerage services from the subject company in the past 12 months. PSBPL or its associates may have received compensation for products or services other than brokerage services from the subject company in the past 12 months. PSBPL or its associates have not received any compensation or other benefits from the Subject Company or third party in connection with the research report. Subject Company may have been client of PSBPL or its associates during twelve months preceding the date of distribution of the research report and PSBPL may have co-managed public offering of securities for the subject company in the past twelve months.

· The research analyst has served as officer, director or employee of the subject company: NO

· Registration granted by SEBI and certification from NISM is in no way guarantee performance of the intermediary or provide any assurance of returns to investors

PSBPL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. Our sales people, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses (if any) may make investment decisions that may be inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution. If this document is sent or has reached any individual in such country, especially, USA, the same may be ignored. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of PSBPL. All trademarks, service marks and logos used in this report are trademarks or registered trademarks of PSBPL or its Group Companies. The information contained herein is not intended for publication or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange B

Terms & Conditions:

This report has been prepared by PSBPL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of PSBPL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and its at discretion of the clients to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. PSBPL will not treat recipients as customers by virtue of their receiving this report.

Registered Office Address:

Progressive Share Brokers Pvt. Ltd, 122-124, Laxmi Plaza, Laxmi Indl Estate, New Link Rd, Andheri West, Mumbai—400053, Maharashtra www.progressiveshares.com | Contact No.:022-40777500.

Compliance Officer:

Ms. Neha Oza,

Email: compliance@progressiveshares.com,

Contact No.:022-40777500.

Grievance Officer: Email: grievancecell@progressiveshares.com